Cipla has entered into definitive agreements to acquire a 100% stake in Inzpera Healthsciences for ₹110.65 crore. With this move, Inzpera Healthsciences will now operate as a wholly owned subsidiary of Cipla.
Source: Cipla Limited Press Release (NSE Exchange Filings) | Published on Nov 03, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Cipla (NSE Exchange Filings), Cipla has entered into definitive agreements to buy Inzpera Healthsciences Pvt Ltd for ₹110.65 crore. This acquisition constitutes a 100% ownership transfer, resulting in Inzpera being a wholly owned subsidiary of Cipla.
The acquisition is a share purchase transaction in which Cipla will acquire all outstanding equity shares of Inzpera Healthsciences. The acquisition is consistent with Cipla's overall goal of strengthening its consumer health segment and expanding its over-the-counter and wellness product portfolio.
Also Read: Zee Media Corporation Announces Appointment Of Raktimanu Das As CEO
Cipla acquires 100% stake in Inzpera Healthsciences.
The deal value is ₹110.65 crore under the definitive agreements.
Inzpera becomes a wholly owned subsidiary of Cipla.
The acquisition is funded through internal accruals.
Transaction strengthens Cipla’s position in consumer healthcare.
The agreement between Cipla and Inzpera Healthsciences outlines the purchase of a 100% equity stake. The transaction is valued at ₹110.65 crore, representing the enterprise value attributed to the target company.
It also covers the purchase of all equity shares and voting rights, enabling full change of control of the business. Upon completion of the transaction, Inzpera Healthsciences Pvt Ltd will be used as a wholly owned subsidiary of Cipla Limited.
The share purchase has been executed in compliance with regulatory norms and standard due diligence procedures.
Particulars  | Details  | 
Acquirer  | Cipla Limited  | 
Target Company  | Inzpera Healthsciences Pvt Ltd  | 
Stake Acquired  | 100%  | 
Deal Value  | ₹110.65 crore  | 
Transaction Type  | Definitive Share Purchase Agreement  | 
Post-Acquisition Status  | Wholly Owned Subsidiary  | 
Source  | BSE and NSE Filings  | 
Inzpera Healthsciences is a part of the consumer health and wellness market, where it creates and sells innovative healthcare products in the nutritional and therapeutic space. The firm carries a broad range of products in pediatric nutrition, gut health, and respiratory care.
The company’s focus is on bridging the gap between prescription-based health and solutions driven by consumer accountability. The firm has a presence in multiple cities in India, supporting Cipla’s mission to expand into preventive and lifestyle health segments.
Cipla share price stands at ₹1,509.60 per share on the NSE as of November 03, 2025, at 15:30 PM IST, up by 0.55 percent from the previous close.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading